The Oncotype DX 21-gene recurrence score helps guide adjuvant therapy in women with early-stage breast cancer and low genomic risk. “Many patients older than 65 years now routinely accept this ...
“ounger patients with low genomic risk breast cancer may reasonably consider de-escalated adjuvant therapy,” the researchers wrote.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback